Emerging therapeutics for the treatment of Friedreich’s ataxia

References

• Vankan P. Prevalence gradients of Friedreich’s ataxia and R1b haplotype in Europe co-localize, suggesting a common Palaeolithic origin in the Franco-Cantabrian ice age refuge. J Neurochem. 2013;126(Suppl 1):11–20.
   PubMed Web of Science ®Google Scholar
• Parkinson MH, Boesch S, Nachbauer W, et al. Clinical features of Friedreich’s ataxia: classical and atypical phenotypes. J Neurochem. 2013;126(Suppl 1):103–117.
   PubMed Web of Science ®Google Scholar
• Delatycki MB, Paris DB, Gardner RJ, et al. Clinical and genetic study of Friedreich ataxia in an Australian population. Am J Med Genet. 1999;87(2):168–174.
   PubMed Web of Science ®Google Scholar
• Filla A, DeMichele G, Caruso G, et al. Genetic data and natural history of Friedreich’s disease: a study of 80 Italian patients. J Neurol. 1990;237(6):345–351.
   PubMed Web of Science ®Google Scholar
• Harding AE. Friedreich’s ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain. 1981;104(3):589–620.
   PubMed Web of Science ®Google Scholar
• Tsou AY, Paulsen EK, Lagedrost SJ, et al. Mortality in Friedreich ataxia. J Neurol Sci. 2011;307(1–2):46–49.
   PubMed Web of Science ®Google Scholar
• Weidemann F, Rummey C, Bijnens B, et al. The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms. Circulation. 2012;125(13):1626–1634.
   PubMed Web of Science ®Google Scholar
• Cnop M, Mulder H, Igoillo-Esteve M. Diabetes in Friedreich ataxia. J Neurochem. 2013;126(Suppl 1):94–102.
   PubMedGoogle Scholar
• Reetz K, Dogan I, Costa AS, et al. Biological and clinical characteristics of the European Friedreich’s Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data. Lancet Neurol. 2015;14(2):174–182.
   PubMed Web of Science ®Google Scholar
• Campuzano V, Montermini L, Molto MD, et al. Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271(5254):1423–1427.
   PubMed Web of Science ®Google Scholar
• Durr A, Cossee M, Agid Y, et al. Clinical and genetic abnormalities in patients with Friedreich’s ataxia. N Engl J Med. 1996;335(16):1169–1175.
   PubMed Web of Science ®Google Scholar
• Pastore A, Puccio H. Frataxin: a protein in search for a function. J Neurochem. 2013;126(Suppl 1):43–52.
   PubMedGoogle Scholar
• Rotig A, De Lonlay P, Chretien D, et al. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat Genet. 1997;17(2):215–217.
   PubMed Web of Science ®Google Scholar
• Adinolfi S, Iannuzzi C, Prischi F, et al. Bacterial frataxin CyaY is the gatekeeper of iron-sulfur cluster formation catalyzed by IscS. Nat Struct Mol Biol. 2009;16(4):390–396.
   PubMed Web of Science ®Google Scholar
• Schmucker S, Martelli A, Colin F, et al. Mammalian frataxin: an essential function for cellular viability through an interaction with a preformed ISCU/NFS1/ISD11 iron-sulfur assembly complex. PLoS One. 2011;6(1):e16199.
   PubMed Web of Science ®Google Scholar
• Yandim C, Natisvili T, Festenstein R. Gene regulation and epigenetics in Friedreich’s ataxia. J Neurochem. 2013;126(Suppl 1):21–42.
   PubMedGoogle Scholar
• Kumari D, Biacsi RE, Usdin K. Repeat expansion affects both transcription initiation and elongation in Friedreich ataxia cells. J Biol Chem. 2011;286(6):4209–4215.
   PubMed Web of Science ®Google Scholar
• Al-Mahdawi S, Pinto RM, Ismail O, et al. The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum Mol Genet. 2008;17(5):735–746.
   PubMed Web of Science ®Google Scholar
• Sakamoto N, Ohshima K, Montermini L, et al. Sticky DNA, a self-associated complex formed at long GAA*TTC repeats in intron 1 of the frataxin gene, inhibits transcription. J Biol Chem. 2001;276(29):27171–27177.
   PubMed Web of Science ®Google Scholar
• Heidenfelder BL, Makhov AM, Topal MD. Hairpin formation in Friedreich’s ataxia triplet repeat expansion. J Biol Chem. 2003;278(4):2425–2431.
   PubMed Web of Science ®Google Scholar
• Shan Y, Cortopassi G. HSC20 interacts with frataxin and is involved in iron-sulfur cluster biogenesis and iron homeostasis. Hum Mol Genet. 2012;21(7):1457–1469.
   PubMed Web of Science ®Google Scholar
• Shan Y, Napoli E, Cortopassi G. Mitochondrial frataxin interacts with ISD11 of the NFS1/ISCU complex and multiple mitochondrial chaperones. Hum Mol Genet. 2007;16(8):929–941.
   PubMed Web of Science ®Google Scholar
• Gerber J, Muhlenhoff U, Lill R. An interaction between frataxin and Isu1/Nfs1 that is crucial for Fe/S cluster synthesis on Isu1. EMBO Rep. 2003;4(9):906–911.
   PubMed Web of Science ®Google Scholar
• Lodi R, Cooper JM, Bradley JL, et al. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc Natl Acad Sci U S A. 1999;96(20):11492–11495.
   PubMed Web of Science ®Google Scholar
• Ristow M, Pfister MF, Yee AJ, et al. Frataxin activates mitochondrial energy conversion and oxidative phosphorylation. Proc Natl Acad Sci U S A. 2000;97(22):12239–12243.
   PubMed Web of Science ®Google Scholar
• Koeppen AH, Mazurkiewicz JE. Friedreich ataxia: neuropathology revised. J Neuropathol Exp Neurol. 2013;72(2):78–90.
   PubMed Web of Science ®Google Scholar
• Babcock M, De Silva D, Oaks R, et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science. 1997;276(5319):1709–1712.
   PubMed Web of Science ®Google Scholar
• Reetz K, Dogan I, Hilgers RD, et al. Progression characteristics of the European Friedreich’s Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study. Lancet Neurol. 2016;15(13):1346–1354.
   PubMed Web of Science ®Google Scholar
• Patel M, Isaacs CJ, Seyer L, et al. Progression of Friedreich ataxia: quantitative characterization over 5 years. Ann Clin Transl Neurol. 2016;3(9):684–694.
   PubMed Web of Science ®Google Scholar
• Burk K, Schulz SR, Schulz JB. Monitoring progression in Friedreich ataxia (FRDA): the use of clinical scales. J Neurochem. 2013;126(Suppl 1):118–124.
   PubMedGoogle Scholar
• Trouillas P, Takayanagi T, Hallett M, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci. 1997;145(2):205–211.
   PubMed Web of Science ®Google Scholar
• Metz G, Coppard N, Cooper JM, et al. Rating disease progression of Friedreich’s ataxia by the International Cooperative Ataxia Rating Scale: analysis of a 603-patient database. Brain. 2013;136(Pt 1):259–268.
   PubMed Web of Science ®Google Scholar
• Subramony SH, May W, Lynch D, et al. Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology. 2005;64(7):1261–1262.
   PubMed Web of Science ®Google Scholar
• Fahey MC, Corben L, Collins V, et al. How is disease progress in Friedreich’s ataxia best measured? A study of four rating scales. J Neurol Neurosurg Psychiatry. 2007;78(4):411–413.
   PubMed Web of Science ®Google Scholar
• Schmitz-Hubsch T, Du Montcel ST, Baliko L, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006;66(11):1717–1720.
   PubMed Web of Science ®Google Scholar
• Burk K, Malzig U, Wolf S, et al. Comparison of three clinical rating scales in Friedreich ataxia (FRDA). Mov Disord. 2009;24(12):1779–1784.
   PubMed Web of Science ®Google Scholar
• Filipovic Pierucci A, Mariotti C, Panzeri M, et al. Quantifiable evaluation of cerebellar signs in children. Neurology. 2015;84(12):1225–1232.
   PubMed Web of Science ®Google Scholar
• Mariotti C, Solari A, Torta D, et al. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology. 2003;60(10):1676–1679.
   PubMed Web of Science ®Google Scholar
• Buyse G, Mertens L, Di Salvo G, et al. Idebenone treatment in Friedreich’s ataxia: neurological, cardiac, and biochemical monitoring. Neurology. 2003;60(10):1679–1681.
   PubMed Web of Science ®Google Scholar
• Arpa J, Sanz-Gallego I, Rodriguez-de-Rivera FJ, et al. Triple therapy with darbepoetin alfa, idebenone, and riboflavin in Friedreich’s ataxia: an open-label trial. Cerebellum. 2013;12(5):713–720.
   PubMed Web of Science ®Google Scholar
• Reata Pharmaceuticals, Inc. Announces positive data from part one of moxie trial of omaveloxolone for Friedreich’s Ataxia [press release]. Available from: http://news.reatapharma.com/phoenix.zhtml?c=254306&p=irol-newsArticle&ID=2278245.
   Google Scholar
• Heerinck F, Shaw J, Shchepinov M, et al. RT001 first-in human clinical trial demonstrates safety, favorable pharmacokinetics, and early signals of efficacy in Friedreich’s Ataxia. International Ataxia Research Conference 2017; 2017; Pisa, Italy.
   Google Scholar
• Drinkard BE, Keyser RE, Paul SM, et al. Exercise capacity and idebenone intervention in children and adolescents with Friedreich ataxia. Arch Phys Med Rehabil. 2010;91(7):1044–1050.
   PubMed Web of Science ®Google Scholar
• Chateauvieux S, Grigorakaki C, Morceau F, et al. Erythropoietin, erythropoiesis and beyond. Biochem Pharmacol. 2011;82(10):1291–1303.
   PubMed Web of Science ®Google Scholar
• Miller JL, Church TJ, Leonoudakis D, et al. Discovery and characterization of nonpeptidyl agonists of the tissue-protective erythropoietin receptor. Mol Pharmacol. 2015;88(2):357–367.
   PubMed Web of Science ®Google Scholar
• Tan CC, Eckardt KU, Firth JD, et al. Feedback modulation of renal and hepatic erythropoietin mRNA in response to graded anemia and hypoxia. Am J Physiol. 1992;263(3 Pt 2):F474–81.
   PubMedGoogle Scholar
• Sturm B, Stupphann D, Kaun C, et al. Recombinant human erythropoietin: effects on frataxin expression in vitro. Eur J Clin Invest. 2005;35(11):711–717.
   PubMed Web of Science ®Google Scholar
• Sturm B, Helminger M, Steinkellner H, et al. Carbamylated erythropoietin increases frataxin independent from the erythropoietin receptor. Eur J Clin Invest. 2010;40(6):561–565.
   PubMed Web of Science ®Google Scholar
• Miller JL, Rai M, Frigon NL, et al. Erythropoietin and small molecule agonists of the tissue-protective erythropoietin receptor increase FXN expression in neuronal cells in vitro and in Fxn-deficient KIKO mice in vivo. Neuropharmacology. 2017;123:34–45.
   PubMed Web of Science ®Google Scholar
• Acquaviva F, Castaldo I, Filla A, et al. Recombinant human erythropoietin increases frataxin protein expression without increasing mRNA expression. Cerebellum. 2008;7(3):360–365.
   PubMed Web of Science ®Google Scholar
• Boesch S, Sturm B, Hering S, et al. Friedreich’s ataxia: clinical pilot trial with recombinant human erythropoietin. Ann Neurol. 2007;62(5):521–524.
   PubMed Web of Science ®Google Scholar
• Boesch S, Sturm B, Hering S, et al. Neurological effects of recombinant human erythropoietin in Friedreich’s ataxia: a clinical pilot trial. Mov Disord. 2008;23(13):1940–1944.
   PubMed Web of Science ®Google Scholar
• Nachbauer W, Hering S, Seifert M, et al. Effects of erythropoietin on frataxin levels and mitochondrial function in Friedreich ataxia–a dose-response trial. Cerebellum. 2011;10(4):763–769.
   PubMed Web of Science ®Google Scholar
• Mariotti C, Fancellu R, Caldarazzo S, et al. Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial. Mov Disord. 2012;27(3):446–449.
   PubMed Web of Science ®Google Scholar
• Boesch S, Nachbauer W, Mariotti C, et al. Safety and tolerability of carbamylated erythropoietin in Friedreich’s ataxia. Mov Disord. 2014;29(7):935–939.
   PubMed Web of Science ®Google Scholar
• Herman D, Jenssen K, Burnett R, et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich’s ataxia. Nat Chem Biol. 2006;2(10):551–558.
   PubMed Web of Science ®Google Scholar
• Saveliev A, Everett C, Sharpe T, et al. DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature. 2003;422(6934):909–913.
   PubMed Web of Science ®Google Scholar
• Soragni E, Gottesfeld JM. Translating HDAC inhibitors in Friedreich’s ataxia. Expert Opin Orphan Drugs. 2016;4(9):961–970.
   PubMed Web of Science ®Google Scholar
• Chan PK, Torres R, Yandim C, et al. Heterochromatinization induced by GAA-repeat hyperexpansion in Friedreich’s ataxia can be reduced upon HDAC inhibition by vitamin B3. Hum Mol Genet. 2013;22(13):2662–2675.
   PubMed Web of Science ®Google Scholar
• Libri V, Yandim C, Athanasopoulos S, et al. Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich’s ataxia: an exploratory, open-label, dose-escalation study. Lancet. 2014;384(9942):504–513.
   PubMed Web of Science ®Google Scholar
• NICOFA - Nicotinamide for the treatment of Friedreich ataxia. Available from: http://www.erare.eu/financed-projects/nicofa
   Google Scholar
• Soragni E, Miao W, Iudicello M, et al. Epigenetic therapy for Friedreich ataxia. Ann Neurol. 2014;76(4):489–508.
   PubMed Web of Science ®Google Scholar
• Martin AS, Abraham DM, Hershberger KA, et al. Nicotinamide mononucleotide supplementation in a model of Friedreich’s Ataxia cardiomyopathy improves cardiac function and bioenergetics in a SIRT3-dependent manner. International Ataxia Research Conference; Pisa, Italy; 2017.
   Google Scholar
• Vang O, Ahmad N, Baile CA, et al. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One. 2011;6(6):e19881.
   PubMed Web of Science ®Google Scholar
• Li L, Voullaire L, Sandi C, et al. Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia. PLoS One. 2013;8(2):e55940.
   PubMed Web of Science ®Google Scholar
• Yiu EM, Tai G, Peverill RE, et al. An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels. J Neurol. 2015;262(5):1344–1353.
   PubMed Web of Science ®Google Scholar
• Ren J, Fan C, Chen N, et al. Resveratrol pretreatment attenuates cerebral ischemic injury by upregulating expression of transcription factor Nrf2 and HO-1 in rats. Neurochem Res. 2011;36(12):2352–2362.
   PubMed Web of Science ®Google Scholar
• Cottart CH, Nivet-Antoine V, Beaudeux JL. Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. Mol Nutr Food Res. 2014;58(1):7–21.
   PubMed Web of Science ®Google Scholar
• Young HA, Bream JH. IFN-gamma: recent advances in understanding regulation of expression, biological functions, and clinical applications. Curr Top Microbiol Immunol. 2007;316:97–117.
   PubMed Web of Science ®Google Scholar
• Ganz T. Iron in innate immunity: starve the invaders. Curr Opin Immunol. 2009;21(1):63–67.
   PubMed Web of Science ®Google Scholar
• Tomassini B, Arcuri G, Fortuni S, et al. Interferon gamma upregulates frataxin and corrects the functional deficits in a Friedreich ataxia model. Hum Mol Genet. 2012;21(13):2855–2861.
   PubMed Web of Science ®Google Scholar
• Seyer L, Greeley N, Foerster D, et al. Open-label pilot study of interferon gamma-1b in Friedreich ataxia. Acta Neurol Scand. 2015;132(1):7–15.
   PubMed Web of Science ®Google Scholar
• Marcotulli C, Fortuni S, Arcuri G, et al. GIFT-1, a phase IIa clinical trial to test the safety and efficacy of IFN gamma administration in FRDA patients. Neurol Sci. 2016;37(3):361–364.
   PubMed Web of Science ®Google Scholar
• Horizon pharma plc announces topline results from phase 3 study of ACTIMMUNE® (interferon gamma-1b) in Friedreich’s Ataxia. Available from: http://ir.horizon-pharma.com/news-releases/news-release-details/horizon-pharma-plc-announces-topline-results-phase-3-study
   Google Scholar
• Perdomini M, Belbellaa B, Monassier L, et al. Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich’s ataxia. Nat Med. 2014;20(5):542–547.
   PubMed Web of Science ®Google Scholar
• Piguet F, Vaucamps N, De Montigny C, et al. Correction of sensory ataxia in a novel mouse model of Friedreich ataxia using gene therapy approach. International Ataxia Research Conference; Pisa, Italy; 2017.
   Google Scholar
• Ouellet DL, Cherif K, Rousseau J, et al. Deletion of the GAA repeats from the human frataxin gene using the CRISPR-Cas9 system in YG8R-derived cells and mouse models of Friedreich ataxia. Gene Ther. 2017;24(5):265–274.
   PubMed Web of Science ®Google Scholar
• Nabhan JF, Wood KM, Rao VP, et al. Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich’s ataxia. Sci Rep. 2016;6:20019.
   PubMed Web of Science ®Google Scholar
• Li L, Matsui M, Corey DR. Activating frataxin expression by repeat-targeted nucleic acids. Nat Commun. 2016;7:10606.
   PubMed Web of Science ®Google Scholar
• Vyas PM, Tomamichel WJ, Pride PM, et al. A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich’s ataxia mouse model. Hum Mol Genet. 2012;21(6):1230–1247.
   PubMed Web of Science ®Google Scholar
• Benini M, Fortuni S, Condo I, et al. E3 ligase RNF126 directly ubiquitinates frataxin, promoting its degradation: identification of a potential therapeutic target for Friedreich Ataxia. Cell Rep. 2017;18(8):2007–2017.
   PubMed Web of Science ®Google Scholar
• Wong A, Yang J, Cavadini P, et al. The Friedreich’s ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum Mol Genet. 1999;8(3):425–430.
   PubMed Web of Science ®Google Scholar
• Orsucci D, Mancuso M, Ienco EC, et al. Targeting mitochondrial dysfunction and neurodegeneration by means of coenzyme Q10 and its analogues. Curr Med Chem. 2011;18(26):4053–4064.
   PubMed Web of Science ®Google Scholar
• Esposti MD, Ngo A, Ghelli A, et al. The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria. Arch Biochem Biophys. 1996;330(2):395–400.
   PubMed Web of Science ®Google Scholar
• Cooper JM, Korlipara LV, Hart PE, et al. Coenzyme Q10 and vitamin E deficiency in Friedreich’s ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy. Eur J Neurol. 2008;15(12):1371–1379.
   PubMed Web of Science ®Google Scholar
• Hart PE, Lodi R, Rajagopalan B, et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol. 2005;62(4):621–626.
   PubMedGoogle Scholar
• Lodi R, Hart PE, Rajagopalan B, et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich’s ataxia. Ann Neurol. 2001;49(5):590–596.
   PubMed Web of Science ®Google Scholar
• Artuch R, Aracil A, Mas A, et al. Friedreich’s ataxia: idebenone treatment in early stage patients. Neuropediatrics. 2002;33(4):190–193.
   PubMed Web of Science ®Google Scholar
• Brandsema JF, Stephens D, Hartley J, et al. Intermediate-dose idebenone and quality of life in Friedreich ataxia. Pediatr Neurol. 2010;42(5):338–342.
   PubMed Web of Science ®Google Scholar
• Hausse AO, Aggoun Y, Bonnet D, et al. Idebenone and reduced cardiac hypertrophy in Friedreich’s ataxia. Heart. 2002;87(4):346–349.
   PubMed Web of Science ®Google Scholar
• Pineda M, Arpa J, Montero R, et al. Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur J Paediatr Neurol. 2008;12(6):470–475.
   PubMed Web of Science ®Google Scholar
• Rustin P, Rotig A, Munnich A, et al. Heart hypertrophy and function are improved by idebenone in Friedreich’s ataxia. Free Radic Res. 2002;36(4):467–469.
   PubMed Web of Science ®Google Scholar
• Rustin P, von Kleist-Retzow JC, Chantrel-Groussard K, et al. Effect of idebenone on cardiomyopathy in Friedreich’s ataxia: a preliminary study. Lancet. 1999;354(9177):477–479.
   PubMed Web of Science ®Google Scholar
• Di Prospero NA, Baker A, Jeffries N, et al. Neurological effects of high-dose idebenone in patients with Friedreich’s ataxia: a randomised, placebo-controlled trial. Lancet Neurol. 2007;6(10):878–886.
   PubMed Web of Science ®Google Scholar
• Lagedrost SJ, Sutton MS, Cohen MS, et al. Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA). Am Heart J. 2011;161(3):639–45 e1.
   PubMed Web of Science ®Google Scholar
• Lynch DR, Perlman SL, Meier T. A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia. Arch Neurol. 2010;67(8):941–947.
   PubMed Web of Science ®Google Scholar
• Meier T, Perlman SL, Rummey C, et al. Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich’s ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. J Neurol. 2012;259(2):284–291.
   PubMed Web of Science ®Google Scholar
• Parkinson MH, Schulz JB, Giunti P. Co-enzyme Q10 and idebenone use in Friedreich’s ataxia. J Neurochem. 2013;126(Suppl 1):125–141.
   PubMed Web of Science ®Google Scholar
• Hawi A, Heald S, Sciascia T. Use of an adaptive study design in single ascending-dose pharmacokinetics of A0001 (alpha-tocopherylquinone) in healthy male subjects. J Clin Pharmacol. 2012;52(1):65–77.
   PubMed Web of Science ®Google Scholar
• Lynch DR, Willi SM, Wilson RB, et al. A0001 in Friedreich ataxia: biochemical characterization and effects in a clinical trial. Mov Disord. 2012;27(8):1026–1033.
   PubMed Web of Science ®Google Scholar
• Martinelli D, Catteruccia M, Piemonte F, et al. EPI-743 reverses the progression of the pediatric mitochondrial disease–genetically defined Leigh Syndrome. Mol Genet Metab. 2012;107(3):383–388.
   PubMed Web of Science ®Google Scholar
• Zesiewicz T, Perlman S, Sullivan K, et al., editors. EPI-743 (Alpha-tocotrienol Quinone) Demonstrates Long-Term Improvement in Neurological Function and Disease Progression in Friedreich’s Ataxia AAN 69th Annual Meeting; Boston; 2017.
   Google Scholar
• Sullivan K, Freeman M, Shaw J, et al., editors. EPI-743 for Friedreich’s Ataxia Patients with Point Mutations AAN 69th Annual Meeting; Boston;2017.
   Google Scholar
• Chyan YJ, Poeggeler B, Omar RA, et al. Potent neuroprotective properties against the Alzheimer beta-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid. J Biol Chem. 1999;274(31):21937–21942.
   PubMed Web of Science ®Google Scholar
• Safety and Pharmacology Study of VP 20629 in Adults With Friedreich’s Ataxia. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01898884?term=VP-20629&rank=12016
   Google Scholar
• Cotticelli MG, Crabbe AM, Wilson RB, et al. Insights into the role of oxidative stress in the pathology of Friedreich ataxia using peroxidation resistant polyunsaturated fatty acids. Redox Biol. 2013;1:398–404.
   PubMed Web of Science ®Google Scholar
• A First in Human Study of RT001 in Patients With Friedreich’s Ataxia. Available from: https://clinicaltrials.gov/ct2/show/NCT02445794?term=RT001&draw=1&rank=2
   Google Scholar
• Retrotope Announces Phase I/II Clinical Trial Results of RT001 in Treatment of Friedreich’s ataxia [press release]. Available from: https://static1.squarespace.com/static/549af14ae4b004237f7bb71a/t/57dd7786f7e0ab741930775f/1474131955350/PR+Retrotope+Phase+1+Results.pdf
   Google Scholar
• Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia Available from: https://clinicaltrials.gov/ct2/show/NCT00824512?cond=EGb761&draw=1&rank=1.
   Google Scholar
• Infante JP, Huszagh VA. Secondary carnitine deficiency and impaired docosahexaenoic (22: 6n-3)acid synthesis: a common denominator in the pathophysiology of diseases of oxidative phosphorylation and beta-oxidation. FEBS Lett. 2000;468(1):1–5.
   PubMed Web of Science ®Google Scholar
• Schols L, Zange J, Abele M, et al. L-carnitine and creatine in Friedreich’s ataxia. A randomized, placebo-controlled crossover trial. J Neural Transm (Vienna). 2005;112(6):789–796.
   PubMed Web of Science ®Google Scholar
• An Open-label Study of the Effects of Acetyl-L-Carnitine on Cardiovascular Outcomes in Friedreich’s Ataxia 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT01921868?recrs=ab&cond=An+Open-label+Study+of+the+Effects+of+Acetyl-L-Carnitine+on+Cardiovascular+Outcomes+in+Friedreich%27s+Ataxia&rank=1.
   Google Scholar
• Moreno-Ulloa A, Nogueira L, Rodriguez A, et al. Recovery of indicators of mitochondrial biogenesis, oxidative stress, and aging with (−)-epicatechin in senile mice. J Gerontol A Biol Sci Med Sci. 2015;70(11):1370–1378.
   PubMed Web of Science ®Google Scholar
• Ramirez-Sanchez I, Rodriguez A, Moreno-Ulloa A, et al. (−)-Epicatechin-induced recovery of mitochondria from simulated diabetes: potential role of endothelial nitric oxide synthase. Diab Vasc Dis Res. 2016;13(3):201–210.
   PubMed Web of Science ®Google Scholar
• (+) Epicatechin to Treat Friedreich’s Ataxia. 2017 Available from: https://clinicaltrials.gov/ct2/show/NCT02660112?cond=%28%2B%29+Epicatechin+to+Treat+Friedreich%27s+Ataxia&rank=1
   Google Scholar
• Wahli W, Braissant O, Desvergne B. Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more. Chem Biol. 1995;2(5):261–266.
   PubMedGoogle Scholar
• Coppola G, Marmolino D, Lu D, et al. Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPAR gamma pathway as a therapeutic target in Friedreich’s ataxia. Hum Mol Genet. 2009;18(13):2452–2461.
   PubMed Web of Science ®Google Scholar
• Marmolino D, Manto M, Acquaviva F, et al. PGC-1alpha down-regulation affects the antioxidant response in Friedreich’s ataxia. PLoS One. 2010;5(4):e10025.
   PubMed Web of Science ®Google Scholar
• Probst BL, Trevino I, McCauley L, et al. RTA 408, a novel synthetic triterpenoid with broad anticancer and anti-inflammatory activity. PLoS One. 2015;10(4):e0122942.
   PubMed Web of Science ®Google Scholar
• Baird L, Dinkova-Kostova AT. The cytoprotective role of the Keap1-Nrf2 pathway. Arch Toxicol. 2011;85(4):241–272.
   PubMed Web of Science ®Google Scholar
• Paupe V, Dassa EP, Goncalves S, et al. Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia. PLoS One. 2009;4(1):e4253.
   PubMed Web of Science ®Google Scholar
• RTA 408 Capsules in Patients With Friedreich’s Ataxia - MOXIe Availble from: https://clinicaltrials.gov/ct2/show/NCT02255435?term=moxie&rank=1
   Google Scholar
• Reilly JF, Yanez G, Bista P, et al. CAT-4001 improves mitochondrial function in a Friedreich’s ataxia model. International Ataxia Research Conference; Pisa, Italy; 2017.
   Google Scholar
• Kakhlon O, Manning H, Breuer W, et al. Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation. Blood. 2008;112(13):5219–5227.
   PubMed Web of Science ®Google Scholar
• Sohn YS, Breuer W, Munnich A, et al. Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood. 2008;111(3):1690–1699.
   PubMed Web of Science ®Google Scholar
• Goncalves S, Paupe V, Dassa EP, et al. Deferiprone targets aconitase: implication for Friedreich’s ataxia treatment. BMC Neurol. 2008;8:20.
   PubMed Web of Science ®Google Scholar
• Pandolfo M, Hausmann L. Deferiprone for the treatment of Friedreich’s ataxia. J Neurochem. 2013;126(Suppl 1):142–146.
   PubMed Web of Science ®Google Scholar
• Boddaert N, Le Quan Sang KH, Rotig A, et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood. 2007;110(1):401–408.
   PubMed Web of Science ®Google Scholar
• Pandolfo M, Arpa J, Delatycki MB, et al. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial. Ann Neurol. 2014;76(4):509–521.
   PubMed Web of Science ®Google Scholar
• Wilson RB, Lynch DR, Fischbeck KH. Normal serum iron and ferritin concentrations in patients with Friedreich’s ataxia. Ann Neurol. 1998;44(1):132–134.
   PubMed Web of Science ®Google Scholar
• Swarup V, Srivastava AK, Padma MV, et al. Quantitative profiling and identification of differentially expressed plasma proteins in Friedreich’s ataxia. J Neurosci Res. 2013;91(11):1483–1491.
   PubMed Web of Science ®Google Scholar
• Rosuvastatin (Crestor) in Friedreich Ataxia. 2017. Available from: https://clinicaltrials.gov/ct2/show/NCT02705547?cond=Rosuvastatin+%28Crestor%29+in+Friedreich+Ataxia&rank=1
   Google Scholar
• Pilot Study of Varenicline (Chantix®) in the Treatment of Friedreich’s Ataxia. 2012. Available from: https://clinicaltrials.gov/ct2/show/NCT00803868?cond=Pilot+Study+of+Varenicline+%28Chantix%C2%AE%29+in+the+Treatment+of+Friedreich%27s+Ataxia&rank=1
   Google Scholar
• Costantini A, Laureti T, Pala MI, et al. Long-term treatment with thiamine as possible medical therapy for Friedreich ataxia. J Neurol. 2016;263(11):2170–2178.
   PubMed Web of Science ®Google Scholar
• Shinnick JE, Isaacs CJ, Vivaldi S, et al. Friedreich Ataxia and nephrotic syndrome: a series of two patients. BMC Neurol. 2016;16:3.
   PubMed Web of Science ®Google Scholar
• Methylprednisolone Treatment of Friedreich Ataxia. 2017. Available from: https://clinicaltrials.gov/ct2/show/NCT02424435?cond=Methylprednisolone+Treatment+of+Friedreich+Ataxia&rank=1.
   Google Scholar
• Schulz JB, Boesch S, Burk K, et al. Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat Rev Neurol. 2009;5(4):222–234.
   PubMed Web of Science ®Google Scholar
• Ilg W, Synofzik M, Brotz D, et al. Intensive coordinative training improves motor performance in degenerative cerebellar disease. Neurology. 2009;73(22):1823–1830.
   PubMed Web of Science ®Google Scholar
• Milne SC, Corben LA, Roberts M, et al. Can rehabilitation improve the health and well-being in Friedreich’s ataxia: a randomized controlled trial?. Clin Rehabil. 2017;269215517736903. [Epub ahead of print].
   PubMedGoogle Scholar
• Si B, Delatycki MB. Friedreich Ataxia. In: Adam MP, Ardinger HH, Pagon RA, et al. editors. GeneReviews(R). Seattle (WA): NCBI Bookshelf. 1993.
   Google Scholar
• Friedman LS, Farmer JM, Perlman S, et al. Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design. Mov Disord. 2010;25(4):426–432.
   PubMed Web of Science ®Google Scholar
• Pousset F, Legrand L, Monin ML, et al. A 22-Year follow-up study of long-term cardiac outcome and predictors of survival in Friedreich Ataxia. JAMA Neurol. 2015;72(11):1334–1341.
   PubMed Web of Science ®Google Scholar
• De Michele G, Perrone F, Filla A, et al. Age of onset, sex, and cardiomyopathy as predictors of disability and survival in Friedreich’s disease: a retrospective study on 119 patients. Neurology. 1996;47(5):1260–1264.
   PubMed Web of Science ®Google Scholar